Boreal Genomics Revenue and Competitors

At Boreal, we are committed to improving cancer patient care through development of research tools and diagnostic tests based on monitoring of circulating tumor DNA in plasma. Boreal's OnTargetâ„¢ platform performs highly sensitive mutation detection to enable accurate tumor profiling and real-time monitoring of tumor evolution from cell-free DNA in plasma. The OnTargetâ„¢ assay is available as a research-use service to reveal tumor mutations that are undetectable with other methods and may help guide selection of therapy, improve clinical trial efficiency, and accelerate drug development programs.